Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TRANSGAMING INC. V.TNG

Technology Electronic Gaming & Multimedia
"TransGaming Inc is engaged in partnering with Smart TV manufacturers and international pay TV operators to deliver interactive gaming experiences to connected TVs globally."

Recent & Breaking News (TSXV:TNG)

Servier et Transgene s’allient pour appliquer les technologies de vectorisation virale à l’ingénierie des CAR-T allogéniques

Business Wire June 29, 2017

Servier and Transgene Have Become Partners to Apply Viral Vectorization Technology to the Engineering of Allogenic CAR-T

Business Wire June 29, 2017

Transgene organise une journée R & D dédiée à l’immuno-oncologie et à la modulation du micro-environnement tumoral

Business Wire June 22, 2017

Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris

Business Wire June 22, 2017

Transgene: Combined General Meeting of June 8, 2017

Business Wire June 8, 2017

Transgene : Assemblée Générale Mixte du 8 juin 2017

Business Wire June 8, 2017

Transgene: UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

Business Wire December 7, 2016

Transgene : UC Davis réalisera un essai clinique de Phase 2 évaluant TG4010 en combinaison avec Opdivo® (nivolumab) en 2ème ligne de traitement du cancer du poumon non à petites cellules (NSCLC) au stade avancé

Business Wire December 7, 2016

IIROC Trading Resumption - FGI; QNC

Canada NewsWire December 5, 2016

Présentation de résultats précliniques de TG1050, une immunothérapie ciblant l’hépatite B chronique au Liver Meeting 2016 de l’AASLD

Business Wire November 14, 2016

Transgene Presents Preclinical Results of TG1050, an HBV-targeted Immunotherapy, at AASLD 2016 Liver Meeting

Business Wire November 14, 2016

Transgene participe au salon Actionaria les 18 et 19 novembre 2016 à Paris

Business Wire November 7, 2016

Transgene : Publication de données précliniques dans OncoImmunology

Business Wire October 28, 2016

Transgene Announces Publication in OncoImmunology of Pre-Clinical Data Demonstrating Delivery of a Fully Functional Immune Checkpoint Inhibitor (ICI) with Anti-Tumor Efficacy by a New Generation of Oncolytic Viral Immunotherapy

Business Wire October 28, 2016

Transgene : Information trimestrielle au 30 septembre 2016

Business Wire October 20, 2016

Transgene Reports Third Quarter 2016 Financial Results

Business Wire October 20, 2016

Transgene annonce une augmentation de capital avec maintien du droit préférentiel de souscription d’un montant d’environ 48 millions d’euros

Business Wire October 20, 2016

Transgene : Randomisation du premier patient recevant des injections répétées dans l’étude de Phase 1/1b de TG1050 pour le traitement de l’hépatite B chronique

Business Wire October 17, 2016

First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients

Business Wire October 17, 2016

Transgene Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study

Business Wire October 11, 2016